She needs a better diet. What is clean to her??
Give me a sample.
I would love to hear what she is doing for training.
We can help her tweak her diet and routine.
Most people think they have a good diet, and it may be better than the diet they had before, but there is always rooms for improvement.
As well, if she is new to training, she may actually put on weigh while losing bodyfat, so you may also want to use bodyfat, bodymeasurements (or how her clothing fits), progress photographs and the scales.
I am not a fan of orlistat/xenical.
Clincal trials haven't shown that significant amount of weight loss, and there are also associated risks with high blood pressure and other heart issues.
People have lost 5 kg/10 lbs over four years.
Long term pharmacotherapy for obesity and overweight: updated meta-analysis -- Rucker et al. 335 (7631): 1194 -- BMJ
What is already known on this topic
Previous meta-analyses examining the long term efficacy of anti-obesity drugs have been limited to orlistat and sibutramine
Average weight losses were less than 5 kg and some cardiovascular risk factors improved, but attrition rates were relatively high
What this study adds
Rimonabant, sibutramine, and orlistat modestly reduce weight (less than 5 kg) and have differing effects on cardiovascular risk factors and differing side effect profiles
There are no data evaluating the effect of anti-obesity drugs on morbidity or mortality end points, although studies are now ongoing
BMJ 2007;335:1194-1199 (8 December), doi:10.1136/bmj.39385.413113.25 (published 15 November 2007)
Research
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker, clinical fellow1, Raj Padwal, assistant professor1, Stephanie K Li, assistant clinical professor1, Cintia Curioni, assistant professor2, David C W Lau, professor3
1 Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2 Department of Nutrition, Faculdade Arthur Sá Earp Neto, Petrópolis, Rio de Janeiro, Brazil, 3 Department of Medicine, University of Calgary, Calgary, AB, Canada
Correspondence to: R Padwal
[email protected]
Objective To summarise the long term efficacy of anti-obesity drugs in reducing weight and improving health status.
Design Updated meta-analysis of randomised trials.
Data sources Medline, Embase, the Cochrane controlled trials register, the Current Science meta-register of controlled trials, and reference lists of identified articles. All data sources were searched from December 2002 (end date of last search) to December 2006.
Studies reviewed Double blind randomised placebo controlled trials of approved anti-obesity dugs used in adults (age over 18) for one year or longer.
Results 30 trials of one to four years’ duration met the inclusion criteria: 16 orlistat (n=10 631 participants), 10 sibutramine (n=2623), and four rimonabant (n=6365). Of these, 14 trials were new and 16 had previously been identified. Attrition rates averaged 30-40%.
Compared with placebo, orlistat reduced weight by 2.9 kg (95% confidence interval 2.5 kg to 3.2 kg), sibutramine by 4.2 kg (3.6 kg to 4.7 kg), and rimonabant by 4.7 kg (4.1 kg to 5.3 kg). Patients receiving active drug treatment were significantly more likely to achieve 5% and 10% weight loss thresholds.
Orlistat reduced the incidence of diabetes and improved concentrations of total cholesterol and low density lipoprotein cholesterol, blood pressure, and glycaemic control in patients with diabetes but increased rates of gastrointestinal side effects and slightly lowered concentrations of high density lipoprotein.
Sibutramine lowered concentrations of high density lipoprotein cholesterol and triglycerides but raised blood pressure and pulse rate. Rimonabant improved concentrations of high density lipoprotein cholesterol and triglycerides, blood pressure, and glycaemic control in patients with diabetes but increased the risk of mood disorders.
Conclusions Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.
Please Scroll Down to See Forums Below 
